Literature DB >> 35567531

The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss.

Chloe S Lalonde1, Yong Teng2, Barbara A Burtness3, Robert L Ferris4, Rafi Ahmed5, Nabil F Saba2.   

Abstract

Oropharyngeal squamous cell carcinoma (OPSCC) accounts for more than half of all head and neck cancers. Since the 1970s, OPSCC has shifted from an environmentally triggered to virally mediated disease due to a sharp rise in human papillomavirus (HPV)-related squamous cell carcinoma. Although a highly effective prophylactic vaccine is available, its current implementation is far below national targets, and OPSCC incidence is predicted to further increase by 2045. However, we believe that with prompt action now, we can not only defy these predictions but also effectively eradicate HPV-related OPSCC in these next 20 years. We herein provide an overview of the necessary elements to eliminate this disease: improved primary vaccine uptake, a 1-time universal vaccination effort, and implementation of novel therapeutics that have potential to cure existing disease.
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2022        PMID: 35567531      PMCID: PMC9552310          DOI: 10.1093/jnci/djac098

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   11.816


  39 in total

1.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

2.  HPV vaccine promotion: does referring to both cervical cancer and genital warts affect intended and actual vaccination behavior?

Authors:  Ilona Juraskova; Royena Abdul Bari; Michaeley Therese O'Brien; Kirsten Jo McCaffery
Journal:  Womens Health Issues       Date:  2011 Jan-Feb

Review 3.  Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region.

Authors:  Hisham Mehanna; Tom Beech; Tom Nicholson; Iman El-Hariry; Christopher McConkey; Vinidh Paleri; Sally Roberts
Journal:  Head Neck       Date:  2012-01-20       Impact factor: 3.147

4.  Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis.

Authors:  G M Clifford; S Gallus; R Herrero; N Muñoz; P J F Snijders; S Vaccarella; P T H Anh; C Ferreccio; N T Hieu; E Matos; M Molano; R Rajkumar; G Ronco; S de Sanjosé; H R Shin; S Sukvirach; J O Thomas; S Tunsakul; C J L M Meijer; S Franceschi
Journal:  Lancet       Date:  2005 Sep 17-23       Impact factor: 79.321

Review 5.  Epidemiology of HPV-associated oropharyngeal cancer.

Authors:  Kristen B Pytynia; Kristina R Dahlstrom; Erich M Sturgis
Journal:  Oral Oncol       Date:  2014-01-22       Impact factor: 5.337

Review 6.  Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.

Authors:  Joseph G Skeate; Andrew W Woodham; Mark H Einstein; Diane M Da Silva; W Martin Kast
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

Review 7.  Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature.

Authors:  Dawn M Holman; Vicki Benard; Katherine B Roland; Meg Watson; Nicole Liddon; Shannon Stokley
Journal:  JAMA Pediatr       Date:  2014-01       Impact factor: 16.193

8.  Age of Acquiring Causal Human Papillomavirus (HPV) Infections: Leveraging Simulation Models to Explore the Natural History of HPV-induced Cervical Cancer.

Authors:  Emily A Burger; Jane J Kim; Stephen Sy; Philip E Castle
Journal:  Clin Infect Dis       Date:  2017-09-15       Impact factor: 9.079

9.  Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).

Authors:  Robert L Ferris; Yael Flamand; Gregory S Weinstein; Shuli Li; Harry Quon; Ranee Mehra; Joaquin J Garcia; Christine H Chung; Maura L Gillison; Umamaheswar Duvvuri; Bert W O'Malley; Enver Ozer; Giovana R Thomas; Wayne M Koch; Neil D Gross; R Bryan Bell; Nabil F Saba; Miriam Lango; Eduardo Méndez; Barbara Burtness
Journal:  J Clin Oncol       Date:  2021-10-26       Impact factor: 50.717

10.  Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.

Authors:  Marc Brisson; Jane J Kim; Karen Canfell; Mélanie Drolet; Guillaume Gingras; Emily A Burger; Dave Martin; Kate T Simms; Élodie Bénard; Marie-Claude Boily; Stephen Sy; Catherine Regan; Adam Keane; Michael Caruana; Diep T N Nguyen; Megan A Smith; Jean-François Laprise; Mark Jit; Michel Alary; Freddie Bray; Elena Fidarova; Fayad Elsheikh; Paul J N Bloem; Nathalie Broutet; Raymond Hutubessy
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.